Sermorelin + Ipamorelin: The GH Pulse Extension Stack

What this stack does

Sermorelin and Ipamorelin are both growth-hormone-releasing peptides (GHRPs), but they work through distinct mechanisms. Sermorelin is a synthetic analog of GHRH (growth-hormone-releasing hormone), which signals the anterior pituitary to release stored GH. Ipamorelin is a selective ghrelin receptor agonist that triggers GH release through a different pathway, with minimal impact on cortisol or prolactin elevation.

Stacking them extends the duration and amplitude of the body's natural GH pulse. Research shows that Ipamorelin's ghrelin-like signaling amplifies and sustains the GH release initiated by Sermorelin's GHRH-mimetic action. The combined effect is broader pulse coverage without the sustained elevation that longer-acting compounds like CJC-1295 produce. Users report a gentler metabolic signature: less hunger dysregulation, lower cortisol spillover, and more gradual improvements in recovery markers.

The stack is most relevant for men returning from soft-tissue injury or layoff, where the goal is to restore the natural GH rhythm that supports collagen turnover and connective-tissue adaptation. Neither compound directly builds muscle in the traditional sense, but GH elevation improves nitrogen retention, joint lubrication, and sleep architecture, all of which enable better training outcomes.

Who it's for

High-performing men 35+ recovering from injury or extended training layoff. The stack suits those who have noticed slower recovery times, diminished sleep quality, or soft-tissue resilience issues (shoulder, knee, hip). It is especially relevant after acute injury (post-surgery, torn rotator cuff, meniscal repair) where endogenous GH support can accelerate healing phases.

This stack appeals to men skeptical of long-acting GH secretagogues but wanting more than peptide monotherapy. You're interested in working with your body's natural pulse rhythm rather than forcing supraphysiological levels. You read the research, track recovery biomarkers (cortisol, IGF-1), and prefer a protocol with a narrower side-effect window.

It is not designed for primary muscle-building or fat-loss. If your goal is maximal lean-mass accretion or dramatic body recomposition, other stacks (including higher-dose protocols or longer-acting secretagogues) will outperform this one. This stack prioritizes recovery quality and physiological alignment.

The protocol

Sermorelin: 100 micrograms (100 mcg) per injection, subcutaneous, once daily. Administer 30-60 minutes before bed or upon waking, depending on preference. Most users prefer evening dosing to align with the body's natural nocturnal GH surge. Reconstitute with bacteriostatic water per the reconstitution calculator. Shelf-life after reconstitution is 14-30 days refrigerated (2-8°C).

Ipamorelin: 100 micrograms (100 mcg) per injection, subcutaneous, once or twice daily. If dosing once daily, combine with Sermorelin at the same time (same injection or separate sites, 1-2 minutes apart). If dosing twice daily, inject the second dose 4-6 hours later (e.g., morning and evening). Ipamorelin has a shorter half-life (2 hours) than Sermorelin (7-15 minutes), so splitting doses can extend pulse coverage. Reconstitution and storage protocols match Sermorelin.

Cycle structure: 12 weeks on, 2-4 weeks off. This allows endogenous GH signaling to reset and prevents tachyphylaxis (desensitization of the pituitary to the peptide signal). Anecdotally, users who cycle report sustained responsiveness across multiple 12-week blocks; those who run continuously for 16+ weeks often report diminished effects by week 14-15.

Timing within the day: Evening dosing (30-60 min before bed) is preferred, as it aligns with the body's natural GH pulse and supports sleep consolidation. If twice-daily dosing, morning injection can be 30-60 min post-waking; second injection 4-6 hours later or 30-60 min before bed.

Food state: Neither compound requires fasting, but a light meal 30-60 min before injection may reduce nausea. Avoid heavy fat intake immediately before or after injection, as it can slow subcutaneous absorption.

Washout: After the final injection, GH levels return to baseline within 24-48 hours. No extended washout is necessary, but the 2-4 week off-cycle is recommended to allow pituitary downregulation to recover and maintain long-term peptide efficacy.

What to expect, week by week

Week 1-2: Injection tolerance and technique refinement. Most users report minimal local reaction (occasional mild injection-site erythema). Sleep quality may deepen by night 3-4. Appetite often increases slightly within 48 hours (ghrelin-pathway activation via Ipamorelin). No dramatic change in energy or recovery markers yet.

Week 4: Sleep architecture improves noticeably: deeper NREM3 (slow-wave sleep), shorter sleep-onset latency, reduced nighttime awakenings. Recovery perception shifts: soreness resolves faster, nagging joint stiffness diminishes. Fasting IGF-1 may rise 10-20%, though baseline-to-peak variability is high. Strength or endurance gains are not expected; recovery metrics lead performance gains by 4-6 weeks.

Week 8: Connective-tissue resilience becomes apparent if you are training consistently. Soft-tissue injuries show signs of faster adaptation (post-injury inflammation resolves sooner, ROM improves). Users report sustained improvements in sleep quality and energy within 1-2 hours post-injection (attributed to GH-mediated mood and metabolic tone). Fasting cortisol may trend downward if baseline was elevated. Body composition changes are minimal; fat loss is not a primary effect of this stack.

Week 12: Cumulative improvements in recovery capacity support higher training volume tolerance. Injury healing landmarks (e.g., return to full ROM, pain-free load) are often visible in post-injury cohorts. Some users report modest lean-mass gain (2-3 lbs over 12 weeks), but this is secondary to improved sleep and recovery, not direct anabolic effect. Diminishing-return phase begins; this is the natural time to cycle off.

Side effects and safety

Sermorelin: Generally well-tolerated. Reported side effects are mild: transient facial flushing, injection-site erythema, occasional headache or dizziness within 1-2 hours post-injection. No significant impact on cortisol, prolactin, or insulin. Long-term safety data is limited (most published studies are 4-12 weeks), but Sermorelin has been in clinical use for growth-hormone deficiency since the 1990s with a favorable safety record.

Ipamorelin: Selective ghrelin-pathway activation minimizes cortisol and prolactin elevation compared to other GHRPs (e.g., GHRP-6). Side effects are dose-dependent and typically mild: transient appetite increase (within 2-4 hours post-injection), occasional flushing, rare headache. No significant effect on cortisol, prolactin, or hunger hormone dysregulation at 100 mcg doses. Some users report mild water retention (GH-mediated), reversible upon cessation.

Combined stack: Synergistic side effects are rare. The main risk is redundant GH stimulation if dosing is too frequent or too high. Excessive GH elevation (rare at these doses) can increase joint swelling, carpal-tunnel symptoms, or glucose dysregulation in insulin-resistant individuals. Cycling (12 weeks on, 2-4 weeks off) mitigates pituitary downregulation and maintains safety. Monitor fasting glucose and IGF-1 every 8 weeks if you have metabolic risk factors (family history of diabetes, elevated baseline glucose).

Drug interactions: Both peptides are stable in subcutaneous tissue and have minimal systemic absorption kinetics. No significant interactions with oral medications, TRT, or thyroid replacement. If using somatostatin analogs (e.g., octreotide) for other indications, they will suppress GH release and negate this stack's benefit.

Prescription status and access: Sermorelin is available by prescription in most jurisdictions for growth-hormone deficiency. Ipamorelin is not approved by the FDA and exists in a regulatory gray zone in the US; it is available through research-peptide suppliers. Access to both compounds should be via a qualified clinician or compounding pharmacy that verifies your intent and baseline health markers (fasting glucose, IGF-1, lipid panel, cortisol).

Sourcing and quality

Peptide quality directly impacts efficacy and safety. Sermorelin sourced through licensed pharmacies (if prescribed) or compounding facilities with USP/GMP certification is preferred. Ipamorelin sourcing is more opaque; buy only from suppliers with third-party chromatography (HPLC) or mass spectrometry (MS) certificates of analysis. Ensure the supplier tests for endotoxin and bacterial contamination.

Reconstitution is critical. Use only bacteriostatic water (not normal saline or other diluents) to reconstitute lyophilized peptides. Calculate the reconstitution volume using the reconstitution calculator to ensure accurate dosing (e.g., 1 mcg per unit on a standard insulin syringe is common). Store vials at 2-8°C after reconstitution. Discard if visibly discolored, cloudy, or past 30 days post-reconstitution.

Injection technique matters. Use a fresh 30-31 gauge needle for each injection, rotate subcutaneous sites (abdomen, thigh, upper arm), and maintain sterile conditions. Suboptimal injection technique can lead to depot formation (localized pooling) and erratic absorption, which may explain unexpectedly variable outcomes.

FAQ